Understanding and controlling immunogenicity-related risks are attainable objectives, and approvability should not be compromised if these risks are suitably evaluated from the earliest stages of development.
- How to apply immunogenicity risk assessment at the lead candidate selection stage
- Minimizing incremental risks associated with manufacturing
- Understanding what and how to evaluate, at different stages of clinical development
- Integrated presentation of data to regulatory agencies
Read more and register here!